Compare Petróleo Brasileiro SA (PBR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs State Street SPDR S&P Biotech ETF — how do they compare? Petróleo Brasileiro SA trades at $18.93 (market cap $112.59B), while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: Petróleo Brasileiro SA pays a 9.51% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Petróleo Brasileiro SA nearer its low. Which is the better fit depends on your goals.
| PBR | XBI | |
|---|---|---|
Market Cap | $112.59B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $22.03 | $164.28 |
52-Week Low | $11.54 | $85.16 |
Enterprise Value | $176.05B | — |
Dividend Yield | 9.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $18.19, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.73 and robust profitability, including a 21.47% net income margin. Recent news highlights expansion in deepwater operations and strategic partnerships, while earnings have mostly beaten expectations except for a Q1 2026 miss.
The outlook is positive, supported by attractive valuation, solid cash flows, and dividend payments. Risks include oil price volatility and execution of new projects. Analyst consensus leans bullish with 50% buy ratings, but overbought RSI levels suggest near-term caution.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
